Browsing by Author "Kunkel, Louis M."

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Erratum: Skeletal muscle-specific overexpression of miR-486 limits mammary tumor-induced skeletal muscle functional limitations
    (Elsevier, 2022-08-20) Wang, Ruizhong; Kumar, Brijesh; Doud, Emma H.; Mosley, Amber L.; Alexander, Matthew S.; Kunkel, Louis M.; Nakshatri, Harikrishna; Surgery, School of Medicine
    [This corrects the article DOI: 10.1016/j.omtn.2022.03.009.].
  • Thumbnail Image
    Item
    Skeletal muscle-specific overexpression of miR-486 limits mammary tumor-induced skeletal muscle functional limitations
    (Elsevier, 2022-03-16) Wang, Ruizhong; Kumar, Brijesh; Doud, Emma H.; Mosley, Amber L.; Alexander, Matthew S.; Kunkel, Louis M.; Nakshatri, Harikrishna; Surgery, School of Medicine
    miR-486 is a myogenic microRNA, and its reduced skeletal muscle expression is observed in muscular dystrophy. Transgenic overexpression of miR-486 using muscle creatine kinase promoter (MCK-miR-486) partially rescues muscular dystrophy phenotype. We had previously demonstrated reduced circulating and skeletal muscle miR-486 levels with accompanying skeletal muscle defects in mammary tumor models. To determine whether skeletal muscle miR-486 is functionally similar in dystrophies and cancer, we performed functional limitations and biochemical studies of skeletal muscles of MMTV-Neu mice that mimic HER2+ breast cancer and MMTV-PyMT mice that mimic luminal subtype B breast cancer and these mice crossed to MCK-miR-486 mice. miR-486 significantly prevented tumor-induced reduction in muscle contraction force, grip strength, and rotarod performance in MMTV-Neu mice. In this model, miR-486 reversed cancer-induced skeletal muscle changes, including loss of p53, phospho-AKT, and phospho-laminin alpha 2 (LAMA2) and gain of hnRNPA0 and SRSF10 phosphorylation. LAMA2 is a part of the dystrophin-associated glycoprotein complex, and its loss of function causes congenital muscular dystrophy. Complementing these beneficial effects on muscle, miR-486 indirectly reduced tumor growth and improved survival, which is likely due to systemic effects of miR-486 on production of pro-inflammatory cytokines such as IL-6. Thus, similar to dystrophy, miR-486 has the potential to reverse skeletal muscle defects and cancer burden.